Status:

TERMINATED

High Dose Bupropion for Smoking Cessation - Pilot Study

Lead Sponsor:

University of Southern California

Collaborating Sponsors:

University of California, Los Angeles

University of California, San Diego

Conditions:

Smoking Cessation

Smoking, Tobacco

Eligibility:

All Genders

21-65 years

Phase:

PHASE2

Brief Summary

This study aims to investigate the benefit of administering two differing doses of Bupropion (BUP) to smokers to assist with smoking cessation.

Detailed Description

Participants will be randomly assigned to either receive 300 mg of BUP or 450 mg of BUP for 8 weeks with an aim to quit smoking. In addition, participants will simultaneously receive counseling to set...

Eligibility Criteria

Inclusion

  • Smokes cigarettes daily for at least 1 year
  • Breath CO of 5 ppm or higher at Baseline visit
  • Age 21 - 65

Exclusion

  • Possible drug contraindications (panic disorder, bipolar disorder, bulimia, anorexia, insomnia, suicidal ideation, alcohol withdrawal, seizures, severe hypertension, renal/hepatic impairment, angle closure glaucoma)
  • Unstable cardiovascular disorder or uncontrolled hypertension
  • Severe renal/hepatic impairment based on serology evaluation
  • History of seizures, liver failure, central nervous system tumor, central nervous system infection, hypoglycemia, hyponatremia, hypoxia, stroke arteriovenous malformation, head injury
  • Current use of other cessation medication or counseling
  • History of bupropion use
  • Current anti-psychotic, anxiolytic, antidepressant, or psychostimulant medication use, other drugs that may lower seizure threshold, CYP2B6 inhibitors, CYP2B6 inducers, drug metabolized by CYP2D6
  • Sudden stoppage of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs
  • Current (past 30 days) use of illicit or medical use of prescription stimulants
  • Currently or plan to be pregnant or breastfeeding

Key Trial Info

Start Date :

September 1 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2023

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT03326128

Start Date

September 1 2021

End Date

July 1 2023

Last Update

July 17 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Southern California

Los Angeles, California, United States, 90033